Yahoo Web Search

Search results

1. www.atalantatx.comAtalanta Therapeutics » Home

   www.atalantatx.com

   • Cached

   Oct 7, 2021 · Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases. Our founders’ groundbreaking discoveries in RNA interference offer a powerful therapeutic approach to halt diseases at their source. Atalanta's. branched siRNA.

   • Who We Are

     Jenna is joining Atalanta from Voyager Therapeutics, where...

   • our science & focus

     Our therapeutic focus. Our initial areas of therapeutic...

   • patients & families

     Atalanta’s initial therapeutic focus area is Huntington’s...

   • news

     October 14, 2019. Nature Biotechnology “Two new startups,...

   • join us

     Atalanta Therapeutics does not accept unsolicited resumes...

   • contact

     Contact Atalanta Therapeutics. 51 Sleeper Street, 7th Floor...

2. People also ask

   What is Atalanta Therapeutics?

   • Atalanta Therapeutics launched in January, announcing partnerships with Biogen and Genentech and $110 million in series A financing. The company was born from work described in a 2019 Nature Biotechnology paper showing that a chemically synthesized siRNA structure enables durable gene silencing in the brains of mice and non-human primates.

   Atalanta pioneers siRNA for neurodegenerative diseases - Nature

   www.nature.com/articles/s41587-021-00838-2

   See all results for this question

   What is Atalanta doing with Biogen?

   • With Biogen, Atalanta will develop RNAi therapeutics targeting the huntingtin ( HTT) gene, whose mutation causes Huntington’s disease, as well as additional unnamed CNS targets. And its strategic collaboration with Genentech is to develop RNAi therapeutics for neurodegenerative diseases including Parkinson’s disease and Alzheimer’s disease.

   Atalanta pioneers siRNA for neurodegenerative diseases - Nature

   www.nature.com/articles/s41587-021-00838-2

   See all results for this question

   What is Atalanta's partnership with Genentech?

   • And its strategic collaboration with Genentech is to develop RNAi therapeutics for neurodegenerative diseases including Parkinson’s disease and Alzheimer’s disease. Both partnerships include up-front payments to Atalanta, as well as development and milestone payments and royalty payments on any resulting products.

   Atalanta pioneers siRNA for neurodegenerative diseases - Nature

   www.nature.com/articles/s41587-021-00838-2

   See all results for this question

   When did Atalanta Therapeutics start partnering with Biogen & Genentech?

   • Nature Biotechnology 39 , 125 ( 2021) Cite this article Atalanta Therapeutics launched in January, announcing partnerships with Biogen and Genentech and $110 million in series A financing.

   Atalanta pioneers siRNA for neurodegenerative diseases - Nature

   www.nature.com/articles/s41587-021-00838-2

   See all results for this question

3. www.atalantatx.com › who-we-areWho We Are » Atalanta Therapeutics

   www.atalantatx.com › who-we-are

   • Cached

   Jenna is joining Atalanta from Voyager Therapeutics, where she was a part of the in vivo neuroscience group, targeting neurodegenerative diseases using AAV mediated gene therapy. Prior to her time at Voyager, Jenna was at Abpro in the pre-clinical department working in vivo on antibody immunotherapies to target various cancers.

   • 
   • 
   • 
   • 

4. www.atalantatx.com › our-science-focusOur Science & Focus » Atalanta Therapeutics

   www.atalantatx.com › our-science-focus

   • Cached

   Our therapeutic focus. Our initial areas of therapeutic focus will include Huntington’s disease, Parkinson’s disease, and Alzheimer’s disease, alongside other ongoing preclinical research work in other CNS diseases. RNA interference is a Nobel prize-winning discovery that allows for targeted silencing of disease-causing genes.

5. www.linkedin.com › company › atalanta-therapeuticsAtalanta Therapeutics | LinkedIn

   www.linkedin.com › company › atalanta-therapeutics

   Atalanta Therapeutics. 6,092 followers. 10mo. On June 19th 1865, the enslaved people of Galveston, Texas learned they had been emancipated. Originally called "Jubilee Day" in 1866, Juneteenth is ...

6. www.nature.com › articles › s41587/021/00838-2Atalanta pioneers siRNA for neurodegenerative diseases - Nature

   www.nature.com › articles › s41587/021/00838-2

   Feb 9, 2021 · Atalanta Therapeutics launched in January, announcing partnerships with Biogen and Genentech and $110 million in series A financing. The company was born from work described in a 2019 Nature ...

7. cen.acs.org › pharmaceuticals › neuroscienceAtalanta Therapeutics launches to develop RNAi therapies for ...

   cen.acs.org › pharmaceuticals › neuroscience

   • Cached

   Jan 14, 2021 · Atalanta Therapeutics has launched with big plans to develop RNA interference (RNAi) therapies that will silence the expression of genes implicated in neurodegenerative diseases. The new company ...

8. www.nature.com › articles › s41587/020/0452-0Huntington’s antisense drug marches into clinic | Nature ...

   www.nature.com › articles › s41587/020/0452-0

   Mar 9, 2020 · Two new startups, Triplet Therapeutics and Atalanta Therapeutics, are pushing to bring genetic medicine to patients with Huntington’s disease, adding momentum to an industry drive that was ...